Veltara Biosciences
Newsroom

Press release · 21 January 2026

Veltara completes $145 million Series C financing

Proceeds will fund the Phase 2 program for VLT-201 and advance two discovery candidates toward IND.

Veltara Biosciences has completed a $145 million Series C financing led by existing and new institutional investors.

Proceeds will primarily fund the ASCEND-UC Phase 2 study, continued Phase 1 development of VLT-118, and IND-enabling work across the discovery portfolio.